Excluding the injection site skin reactions, which were frequent in patients treated with IL-1 inhibitors, anti-TNF agents accounted for the treatment approach more frequently burdened by a higher frequency of adverse events overall, especially infectious adverse events. Here, TNF is linked to skin reaction.